Related Experiment Video
Updated: Aug 6, 2026
Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients
Published on: October 16, 2016
Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid
Ashik Anil Mathew1, Arulkumaran Rithvik1, Mahaboobkhan Rasool1
1Immunopathology Lab, School of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
Abstract:
Rheumatoid arthritis (RA) and associated inflammatory arthritides are characterized by chronic synovial inflammation that drives destructive pannus formation, eroding cartilage and bone. Current therapies (csDMARDs, bDMARDs, and tsDMARDs) target immune cells and cytokine pathways but yield low rates of full remission, and many patients with residual synovitis continue to damage their joints. Fibroblast-like synoviocytes (FLS) have emerged as key tumor-like mediators of RA. In the inflamed synovium, they expand, resist apoptosis, and secrete pro-inflammatory cytokines, chemokines, and proteases that sustain disease. Directly killing and/or reprogramming these pathogenic FLS is a promising complementary strategy. Recent advances in engineered cell therapies enable specific targeting of stromal cells. In this review, we will discuss novel CAR-based immune cells (CAR-T, CAR-NK, or CAR-macrophages) engineered to target FLS-specific antigens (e.g., fibroblast activation protein) and induce elimination or modulation of FLS. We advocate a primary "safety-first" translational roadmap that integrates features such as transient CAR expression, safety switches, hypoxia-responsive CAR constructs, and localized (intra-articular) delivery to enhance efficacy while avoiding systemic toxicity. Targeted cellular therapies based on this technology may reshape RA therapy as we know it, dismantling the synovial inflammation "engine" with precision and control.
Insights
New cell therapies using engineered immune cells like CAR-T cells show promise for treating rheumatoid arthritis (RA) by targeting specific fibroblast-like synoviocytes (FLS) that drive joint damage.
Area of Science:
- Immunology
- Cell Therapy
- Rheumatology
Background:
- Rheumatoid arthritis (RA) involves chronic synovial inflammation and joint destruction.
- Current RA therapies (csDMARDs, bDMARDs, tsDMARDs) have limited remission rates and fail to halt joint damage in many patients.
- Fibroblast-like synoviocytes (FLS) are key mediators of RA pathogenesis, promoting inflammation and joint erosion.
Purpose of the Study:
- To review novel chimeric antigen receptor (CAR)-based cell therapies engineered to target FLS in RA.
- To discuss strategies for eliminating or modulating pathogenic FLS to complement existing RA treatments.
- To propose a safety-first translational roadmap for developing these targeted cellular therapies.
Main Methods:
- Discussion of CAR-based immune cells (CAR-T, CAR-NK, CAR-macrophages) engineered to target FLS-specific antigens.
- Exploration of targeting fibroblast activation protein (FAP) on FLS.
- Review of safety features for translational development, including transient expression, safety switches, and localized delivery.
Main Results:
- Engineered CAR-immune cells can specifically target and eliminate or modulate FLS.
- Targeting FLS offers a complementary strategy to current RA therapies.
- Proposed safety features aim to enhance efficacy and minimize systemic toxicity.
Conclusions:
- Targeted cellular therapies hold potential to revolutionize RA treatment by precisely dismantling the synovial inflammation engine.
- A safety-first approach is crucial for successful translation of CAR-based FLS-targeting therapies.
- These novel therapies may lead to better disease control and reduced joint damage in RA patients.
